Deals
Impressed by the data to date on bexicaserin for epileptic encephalopathies syndromes, the Danish drugmaker hopes the drug, through the acquisition of Longboard, will become a cornerstone of its new neuro-rare disease franchise.
The French major and partner Denali's attempts to validate RIPK1 as a promising target have once again foundered as oditrasertib comes up short in a multiple sclerosis trial months after a failure in amyotrophic lateral sclerosis.
The biopharma industry posted 22 mergers and acquisitions during the third quarter, according to Evaluate, for a total of $8.2bn. Those tallies marked a second consecutive quarter of decline.
Deal Snapshot: Boehringer Ingelheim will work to develop a cyclin inhibitor that can stop cancer cell growth, using Circle’s macrocycle platform.
Deal Snapshot: The Cambridge, UK-based company could be in line for payments just shy of $2bn if its partnership with the US giant comes up trumps.
The $100m upfront deal help AZ to fill out its cardiovascular, renal and metabolism portfolio, now joining Lilly in seeking to develop an oral Lp(a)-targeting therapy.
Once the deal with Sanofi closes, the rare disease drug will become one of Recordati’s fastest forecast sellers.
CEO Chris Cargill talks to Scrip about Sosei Heptares’ new identity as Nxera, the ups and downs of being big pharma’s go-to small-molecule drug hunter and its move into commercialization in Japan.
Big pharmas, biotechs and the US government look to partner with artificial intelligence and machine learning firms for discovery efforts across therapeutic areas and modalities.
The Swiss group’s head of cardiovascular, renal and metabolism aims to speed its incretins to market, and tackle the plateauing of weight loss and muscle wastage through combinations.
Plus deals involving Jiangsu Alphamab/CSPC, Zydus/CDRI, Junshi/JSIAMA, Repair/Genevant, Sanofi/I-Mab, Novartis/Mitem and BioAtla/Context.
An upfront payment of $110m from BMS has come just in time for Prime Medicine, but its real test will be the first Phase I data, expected early next year.
Deal Snapshot: Merck likes the look of Evaxion's artificial intelligence-based technology platform to develop immunotherapies and signed a biobucks deal that will help ease the Copenhagen-headquartered biotech's financial situation.
Like a previous alliance with Amgen, Generate will use its technology to discover and develop computationally designed therapeutic proteins against multiple undisclosed targets.
Plus deals involving AbbVie/Ripple, Novo Nordisk/Korro Bio, Novo Nordisk/NanoVation, Bharat, Alopexx, Gilead/Genesis, Lilly/Genetic Leap, Contraline/Population Council, Proveca/Cessatech, Vivtex/Equillium and more.
Gilead’s divestment from a 50-50 joint venture with local partner, which came to light recently, will leave China’s cell therapies market under the total control of domestic players in the coming years.
The Italian firm has received "several indications of interest" in evenamide, which is being prepped to go into Phase III for treatment-resistant schizophrenia.
Organon will pay $175m up front for Roivant subsidiary Dermavant and its topical therapy for psoriasis Vtama. The acquirer is betting on growth from adding atopic dermatitis to Vtama’s label.
Also including deals between EpimAb/Vignette, Allist/Jacobio, Rigel/Kissei, Simcere/TargetRx, Altamira/Nuance, PharmaEssentia/Forus and Chugai/LTL.
At the 2024 LSX USA conference, panelists provided advice on how to approach companies in dealmaking and to make their value proposition fit with what the company is looking for.